Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Invested Capital (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Invested Capital for 9 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 17.73% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 17.73% year-over-year, with the annual reading at $1.0 billion for FY2025, 17.73% down from the prior year.
  • Invested Capital for Q4 2025 was $1.0 billion at Denali Therapeutics, up from $931.8 million in the prior quarter.
  • The five-year high for Invested Capital was $1.5 billion in Q1 2024, with the low at $812.7 million in Q3 2022.
  • Average Invested Capital over 5 years is $1.1 billion, with a median of $1.0 billion recorded in 2022.
  • The sharpest move saw Invested Capital surged 113.62% in 2021, then fell 29.63% in 2025.
  • Over 5 years, Invested Capital stood at $962.3 million in 2021, then rose by 8.78% to $1.0 billion in 2022, then dropped by 1.52% to $1.0 billion in 2023, then increased by 20.18% to $1.2 billion in 2024, then dropped by 17.73% to $1.0 billion in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $1.0 billion, $931.8 million, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.